AbCellera to Participate at Upcoming Investor Conferences in November and December 2025Business Wire • 10/07/25
AbCellera Biologics Inc. (ABCL) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 09/29/25
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue EstimatesZacks Investment Research • 08/07/25
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor SymptomsBusiness Wire • 08/07/25
AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 07/31/25
Strength Seen in ABCELLERA BIOLG (ABCL): Can Its 15.0% Jump Turn into More Strength?Zacks Investment Research • 07/22/25
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575Business Wire • 05/30/25
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to MenopauseBusiness Wire • 05/14/25
AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal CircuitBusiness Wire • 05/12/25
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual MeetingBusiness Wire • 05/09/25
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/08/25
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025Business Wire • 04/29/25